in

pharma stocks outlook: Dr Reddy’s, Zydus, Cipla, Sun can sustain low-double digit EPS growth over medium term: Bino Pathiparampil

Bino Pathiparampil, Head of Research, Elara Capital, says companies like Dr Reddy’s, Zydus, Cipla, Sun, can sustain a low-double digit EPS growth over the medium term. Low-double digit is 11%, 12%, 13%, for companies which are offering 12% to 13% earnings growth on a sustainable basis and…

Read More

What do you think?

Written by pulseadmin

Leave a Reply

Your email address will not be published. Required fields are marked *

GIPHY App Key not set. Please check settings

Tata Electronics Widens iPhone Manufacturing Footprint With Pegatron India Acquisition

ICICI Bank Q3 Preview: NII may rise 10% YoY; PAT growth seen stable